Nutriband Inc. (NASDAQ: NTRB)(NASDAQ: NTRBW) announced that its chief executive officer, Gareth Sheridan, will attend the inaugural Nasdaq Life Sciences Advisory Board Biotech Summit on September 16 at Nasdaq MarketSite in New York.

The summit is described as bringing together biotechnology executives, investors, and industry leaders for networking and discussions.

Nutriband is a transdermal pharmaceutical company whose lead product in development is an abuse-deterrent fentanyl patch incorporating its AVERSA™ technology, which embeds aversive agents into transdermal patches to deter abuse, misuse, and accidental exposure.